BACKGROUND: Optimal prevention of late cytomegalovirus (CMV) disease is poorly defined. OBJECTIVE: To compare valganciclovir prophylaxis with polymerase chain reaction-guided preemptive therapy. DESIGN: Randomized, double-blind trial. (ClinicalTrials.gov: NCT00016068). SETTING: Multicenter trial. PATIENTS: 184 recipients of hematopoietic cell transplantation (HCT) who were at high risk for late CMV disease (95 patients receivedvalganciclovir and 89 received placebo). INTERVENTION: 6 months of valganciclovir (900 mg/d) or placebo. Patients with polymerase chain reaction positivity at 1000 copies/mL or greater or a 5-fold increase over baseline were treated withganciclovir or valganciclovir (5 mg/kg or 900 mg twice daily, respectively). MEASUREMENTS: The composite primary end point was death, CMV disease, or other invasive infections by 270 days after HCT. Secondary end points were CMV disease, CMV DNAemia, death, other infections, resource utilization, ganciclovir resistance, quality of life, immune reconstitution, and safety. RESULTS: The primary composite outcome occurred in 20% of valganciclovir recipients versus 21% of placebo-preemptive therapy recipients (treatment difference, -0.01 [95% CI, -0.13 to 0.10]; P = 0.86). There was no difference in the primary end point or its components 640 days after HCT. The incidence of a CMV DNAemia level of 1000 copies/mL or greater or a 5-fold increase over baseline was reduced in the valganciclovir group (11% vs. 36%; P < 0.001). Neutropenia was not significantly different at the absolute neutrophil count of less than 0.5 × 109 cells/L (P = 0.57); however, more patients received hematopoietic growth factors in the valganciclovir group (25.3% vs. 12.4%; P = 0.026). No significant differences were seen in other secondary outcomes. LIMITATION: Some high-risk patients were not included. CONCLUSION:Valganciclovir prophylaxis was not superior in reducing the composite end point of CMV disease, invasive bacterial or fungal disease, or death when compared with polymerase chain reaction-guided preemptive therapy. Both strategies performed similarly with regard to most clinical outcomes. PRIMARY FUNDING SOURCE: Roche Laboratories.
RCT Entities:
BACKGROUND: Optimal prevention of late cytomegalovirus (CMV) disease is poorly defined. OBJECTIVE: To compare valganciclovir prophylaxis with polymerase chain reaction-guided preemptive therapy. DESIGN: Randomized, double-blind trial. (ClinicalTrials.gov: NCT00016068). SETTING: Multicenter trial. PATIENTS: 184 recipients of hematopoietic cell transplantation (HCT) who were at high risk for late CMV disease (95 patients received valganciclovir and 89 received placebo). INTERVENTION: 6 months of valganciclovir (900 mg/d) or placebo. Patients with polymerase chain reaction positivity at 1000 copies/mL or greater or a 5-fold increase over baseline were treated with ganciclovir or valganciclovir (5 mg/kg or 900 mg twice daily, respectively). MEASUREMENTS: The composite primary end point was death, CMV disease, or other invasive infections by 270 days after HCT. Secondary end points were CMV disease, CMV DNAemia, death, other infections, resource utilization, ganciclovir resistance, quality of life, immune reconstitution, and safety. RESULTS: The primary composite outcome occurred in 20% of valganciclovir recipients versus 21% of placebo-preemptive therapy recipients (treatment difference, -0.01 [95% CI, -0.13 to 0.10]; P = 0.86). There was no difference in the primary end point or its components 640 days after HCT. The incidence of a CMV DNAemia level of 1000 copies/mL or greater or a 5-fold increase over baseline was reduced in the valganciclovir group (11% vs. 36%; P < 0.001). Neutropenia was not significantly different at the absolute neutrophil count of less than 0.5 × 109 cells/L (P = 0.57); however, more patients received hematopoietic growth factors in the valganciclovir group (25.3% vs. 12.4%; P = 0.026). No significant differences were seen in other secondary outcomes. LIMITATION: Some high-risk patients were not included. CONCLUSION:Valganciclovir prophylaxis was not superior in reducing the composite end point of CMV disease, invasive bacterial or fungal disease, or death when compared with polymerase chain reaction-guided preemptive therapy. Both strategies performed similarly with regard to most clinical outcomes. PRIMARY FUNDING SOURCE: Roche Laboratories.
Authors: Michael Boeckh; MeeiLi Huang; James Ferrenberg; Terry Stevens-Ayers; Laurence Stensland; W Garrett Nichols; Lawrence Corey Journal: J Clin Microbiol Date: 2004-03 Impact factor: 5.948
Authors: Margaret L Green; Wendy Leisenring; Daniel Stachel; Steven A Pergam; Brenda M Sandmaier; Anna Wald; Lawrence Corey; Michael Boeckh Journal: Biol Blood Marrow Transplant Date: 2012-06-07 Impact factor: 5.742
Authors: Francisco M Marty; Per Ljungman; Genovefa A Papanicolaou; Drew J Winston; Roy F Chemaly; Lynne Strasfeld; Jo-Anne H Young; Tulio Rodriguez; Johan Maertens; Michael Schmitt; Hermann Einsele; Augustin Ferrant; Jeffrey H Lipton; Stephen A Villano; Hongzi Chen; Michael Boeckh Journal: Lancet Infect Dis Date: 2011-03-21 Impact factor: 25.071
Authors: P Ljungman; H Wilczek; G Gahrton; A Gustavsson; G Lundgren; B Lönnqvist; O Ringdén; B Wahren Journal: Bone Marrow Transplant Date: 1986-12 Impact factor: 5.483
Authors: M Kopp; H Schweigkofler; B Holzner; D Nachbaur; D Niederwieser; W W Fleischhacker; G Kemmler; B Sperner-Unterweger Journal: Eur J Haematol Date: 2000-08 Impact factor: 2.997
Authors: Morgan Hakki; Stanley R Riddell; Jan Storek; Rachel A Carter; Terry Stevens-Ayers; Patrick Sudour; Kristen White; Lawrence Corey; Michael Boeckh Journal: Blood Date: 2003-07-03 Impact factor: 22.113
Authors: Michael Maris; Michael Boeckh; Barry Storer; Monja Dawson; Kristen White; Michael Keng; Brenda Sandmaier; David Maloney; Rainer Storb; Jan Storek Journal: Exp Hematol Date: 2003-10 Impact factor: 3.084
Authors: Michael Boeckh; Wendy Leisenring; Stanley R Riddell; Raleigh A Bowden; Meei-Li Huang; David Myerson; Terry Stevens-Ayers; Mary E D Flowers; Terri Cunningham; Lawrence Corey Journal: Blood Date: 2002-09-12 Impact factor: 22.113
Authors: Nina Singh; Drew J Winston; Raymund R Razonable; G Marshall Lyon; Fernanda P Silveira; Marilyn M Wagener; Terry Stevens-Ayers; Bradley Edmison; Michael Boeckh; Ajit P Limaye Journal: JAMA Date: 2020-04-14 Impact factor: 56.272